Skip to main content
Fig. 3 | Annals of Clinical Microbiology and Antimicrobials

Fig. 3

From: Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication

Fig. 3

The Helicobacter pylori eradication rates in susceptibility-guided therapy and empirical vonoprazan-based triple therapy. The differences in the eradication rates between these two therapies (susceptibility-guided therapy minus vonoprazan-based therapy) were 1.9% in the intention-to-treat analysis and − 1.7% in the per-protocol analysis

Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us